Quarterly Result26 May 2026, 01:32 pm
Marksans Pharma FY26: Revenue ₹3,033 Cr, PAT ₹420 Cr
AI Summary
Marksans Pharma Ltd reported its FY26 financial results, achieving its highest-ever total income of approximately ₹3,033 crore, EBITDA of ₹601 crore (margin 20.4%), and PAT of ₹420 crore. The company saw growth driven by new launches across markets, including its Rx branded portfolio in Australia, and a strong recovery in the UK market. The US market also contributed with 112 new SKUs launched. Marksans expanded its global presence by entering new markets like Germany, Canada, and Ireland, and closed the year with a cash balance of approximately ₹990 crore.
Key Highlights
- FY26 total income reached ₹3,033 crore, a 12.8% YoY increase.
- FY26 EBITDA stood at ₹601 crore with a margin of 20.4%.
- US & North America formulation business reported FY26 revenues of ₹1,533 crore.
- UK & Europe formulation business reported FY26 revenues of ₹1015 crore.
- Cash balance as of March 31, 2026, was ₹990 crore.
Price Impact
More from MARKSANS